## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No: 4524

KATO et al.

Art Unit:

1614

Appl. No.: 10/555,343

Examiner:

To be assigned

§ 371 Date: November 1, 2005

Atty. Docket: 1089.0590000/MAC/DJN

For: Freeze-Dried Preparation Containing Methylcobalamin and

**Process For Producing Same** 

First Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering of this Supplemental Information Disclosure Statement is a continuation of Applicants' Information Disclosure Statement filed November 15, 2005.

Copies of documents FP9 and NPL15 are submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document, FP9, cited on Form PTO/SB/08A:

Document FP9, JP 59-152327, is in the Japanese language. An English language abstract of document FP9 is attached as document NPL15. According to document NPL15, FP9 discloses a stabilized vitamin preparation that is prepared by adding at least one type selected from the group consisting of dextran, hydroxyethylstarch, gelatin and reducing saccharides to vitamins, thus being storable for a long period of time.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Daniel J. Nevrivy

Agent for Applicants Registration No. 59,118

Date: May 16, 2007 1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

670322\_1.DOC

Equivalent of Form PTO/SB/08A (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			0	Complete if Known		
EIDET	CIID	DIEN	MENTAL	Application Number	10/555,343	
=				Filing Date	November 1, 2005 (§ 371 Date)	
			DISCLOSURE	First Named Inventor	KATO et al.	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				Art Unit	1614	
			eets as necessary)	Examiner Name	To Be Assigned	
Sheet	1	of	1	Attorney Docket Number	1089.0590000/MAC/DJN	

			U.S. PATENT DO	CUMENTS		
Examiner Cite Initials No. 1	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
initials	NO.	Number-Kind Code <sup>2 (If Known)</sup>	MIMI-DD-1111	Applicant of Cited Document		
	US1					
	US2					
	US3					
<del>.</del>	US4					
	US5					
	US6					
	US7					
	US8					
	US9					
	US10					
	US11					
	US12					
	US13					
	US14					
	US15					
	US16					
	US17					
·	US18					
	US19					
	US20					

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
		Country Code <sup>3</sup> Number <sup>3</sup> Kind Code <sup>5</sup> (if known)			Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
/ZV/	FP9	JP 59-152327	08-31-1984	Otsuka Pharmaceut Co Ltd.			
,	FP10						
	FP11						
	FP12						
	FP13						
	FP14						
	FP15						
	FP16						

670308\_1.DOC

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Con	Complete if Known		
FIRST SUPPLEMENTAL	Application Number	10/555,343		
	Filing Date	November 1, 2005 (§ 371 Date)		
INFORMATION DISCLOSURE	First Named Inventor	KATO et al.		
STATEMENT BY APPLICANT	Art Unit	1614		
(Use as many sheets as necessary)	Examiner Name	To be assigned		
Sheet 1 of 1	Attorney Docket Number	1089.0590000/MAC/DJN		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/ZV/	NPL15	Patent Abstracts of Japan, English language abstract for Publication No. JP 59-152327, Stabilized Vitamin Preparation, published August 31, 1984, (listed on accompanying PTO/SB/08A as document FP1)	
	NPL16		
	NPL17		
	NPL18		
	NPL19		
	NPL20		
	NPL21		
	NPL22		
	NPL23		

670311\_1.DOC

Examiner Signature	/Zohreh Vakili/ (02/15/2008)	Date Considered	/Zohreh Vakili/ (02/15/2008)

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.